



## Comprehensive Care Services for Opioid and Alcohol Use Disorder, and Drug-Resistant Depression

We are writing to share a few updates regarding enhanced and new therapeutic services offered at **Medical Home Development Group (MHDG)**. Our ongoing commitment to deliver holistic, patient-centered care to individuals diagnosed with Substance Use Disorder (SUD) and related conditions has driven us to enhance our services, and we are excited to collaborate more closely with you to ensure the well-being of our patients.

In addition to providing oral **Suboxone (buprenorphine-naloxone)**, MHDG has expanded our Medication-Assisted Treatment (MAT) options to include the administration of **injectable [Brixadi](#) and [Sublocade](#) (both are buprenorphine extended time release)**. These once-monthly injectable formulations provide continuous release of buprenorphine all month long. Expanding this evidence-based approach not only tackles the physical aspects of addiction but also considers the ease of administration, compliance and most importantly, the emotional and psychological well-being of our patients and

For patients diagnosed with Alcohol Use Disorder (AUD), MHDG provides specialized care with once-a-month injectable **Vivitrol (naltrexone)**. Medication therapy, coupled with counseling and peer support play a pivotal role in the comprehensive treatment of AUD and recovery.

MHDG is also the first provider site of **Spravato (esketamine)** for individuals facing Drug-Resistant Depression in the District of Columbia. All District Medicaid Managed Care Organizations cover this therapy for their members with a Prior Authorization. This innovative treatment offers renewed hope for patients who have not responded positively to conventional therapies. Our commitment to mental health care is unwavering, and we are dedicated to providing the highest quality treatment options.

Recognizing the importance of continuity of care as patients transition from inpatient settings to community-based support, we extend our services to all with appointments often within 24-48 hours. MHDG's Care Coordinators also facilitate transportation needs to our facilities and incorporate peer recovery coaches to further bolster their support system during this critical phase of their recovery.

In collaboration with Howard University's College of Pharmacy, MHDG underscores the significance of medication reconciliation services. This collaboration is both in-person and virtual and is especially crucial when treating patients who present with complex comorbid conditions. Our goal is to ensure that each patient's medication regimen is thoughtfully managed and optimized, contributing to their overall health and recovery.

In partnership with RAE Health and the University of Massachusetts, MHDG introduces an innovative program for patients. Participants are equipped with wearable technology featuring algorithms from RAE Health, enabling real-time tracking of cravings, stress, and drug use. The program not only offers tools for de-escalation but also generates personalized treatment data. This collaborative initiative engages and informs treatment providers, while empowering patients to adeptly manage stress, fostering positive changes in their daily lives, thereby leading to a reduction in relapse rates and saving lives.

Thank you for your ongoing dedication to the well-being of our community.

Sidney Nelson, III, MD ABIM, BTP - Lisa B. Sindass, MD, ABPS, BTP - Scott J. Whetsell, FAAP, BTP, FASAM

**\*MHDG is a certified Naloxone (Narcan) site by the Department of Behavioral Health.**